News/ News/ R&D With cash reserves dwindling, Oxurion plans early DME trial readout Phil Taylor diabetic macular oedema, ophthalmology, Oxurion 0 Comment Oxurion will carry out an interim analysis of a phase 2 trial of its last remaining clinical asset Share X With cash reserves dwindling, Oxurion plans early DME trial readout https://pharmaphorum.com/news/with-cash-reserves-dwindling-oxurion-plans-early-dme-trial-readout/
News/ News/ R&D Oxurion craters as failed trial cuts its pipeline down to one Phil Taylor diabetic macular oedema, ophthalmology, Oxurion 0 Comment Shares in Belgian biotech Oxurion are taking a hammering this morning after it reported that one of its Share X Oxurion craters as failed trial cuts its pipeline down to one https://pharmaphorum.com/news/oxurion-craters-as-failed-trial-cuts-its-pipeline-down-to-one/
News/ News/ R&D Oxurion reports stronger data for diabetic eye disease drug Phil Taylor Bayer, diabetic macular oedema, Eylea, ophthalmology, Oxurion, Regeneron 0 Comment Belgian biotech Oxurion has revealed new data from a phase 2 trial of its plasma kallikrein inhibitor THR-149, Share X Oxurion reports stronger data for diabetic eye disease drug https://pharmaphorum.com/news/oxurion-reports-stronger-data-for-diabetic-eye-disease-drug/
